MedTrace Logo

Local Application of Insulin Versus Hyaluronic Acid in Stage III Periodontitis

NCT07746206 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-08-04

No results posted yet for this study

Summary

The present study will be performed on fourty-five patients suffering from periodontitis according to the criteria of American academy of periodontology to evaluate clinically effect of topical application of insulin versus hyaluronic acid as an adjunct to non surgical periodontal therapy in stage Ⅲ periodontitis patients.

This will be done by:

1. Clinical assessment.
2. Biochemical analysis. - Dose the topical application of insulin or hyaluronic acid as an adjunct to non-surgical periodontal therapy improves periodontal condition in stage Ⅲ periodontitis patients? PICO P (Population): patients with stage Ⅲ periodontitis. I (Intervention): non surgical periodontal therapy (SRP) with topical application using insulin or hyaluronic acid in periodontal pockets.

C (Comparison): topical application of insulin versus hyaluronic acid and SRP alone in periodontal pocket.

O (Outcome): primary outcome: change in periodontal pocket depth (PPD) or clinical attachment loss (CAL). Secondary outcome: change in gingival index (GI) or bleeding on probing index (BOP) and levels of IL-1β in GCF of treated pocket.

Study type: Randomized controlled trials (RCTs).

Conditions

  • Treatment of Stage III Periodontitis
  • Local Application of Insulin in Pockets

Interventions

DRUG

Insulin

subgingival scaling and root planning with topical application of insulin gel into periodontal pockets after scaling and root planing.tion of insulin

DRUG

Hyaluronic acid gel

Topical application of hyaluronic acid gel into periodontal pockets after scaling and root planing.

PROCEDURE

mechanical debridement

sub gingival scaling and root planning of periodontal pockets

Sponsors & Collaborators

  • Al-Azhar University

    collaborator OTHER

  • Doaa Atta Aid

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-24
Primary Completion
2026-07-25
Completion
2026-07-25

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07746206 on ClinicalTrials.gov